RxDoctor Payments Data

David van, MD

Family Medicine · Griffin, GANPI 1851452254

Payments from drug & device makers

$11,536in general payments, 2019–2025

Across 501 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$749
  • Pfizer$711
  • Lilly USA, LLC$689
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$9,444100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,536 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$48,407
Medicare patients
175
Services billed
1,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$39,550
JardianceEmpagliflozin16$21,335
FarxigaDapagliflozin Propanediol25$17,825
EliquisApixaban12$11,512
MounjaroTirzepatide11$11,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,426
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,848
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,761
Levothyroxine Sodium94$888
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$822
Rosuvastatin Calcium80$791
Pantoprazole Sodium41$658
Omeprazole42$631
Nebivolol Hcl13$557
FenofibrateFenofibrate Nanocrystallized18$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$667$39,55034 claims
Boehringer IngelheimJardiance$220$21,33516 claims
AstraZenecaFarxiga$1,496$17,82525 claims
PfizerEliquis$711$11,51212 claims
Lilly USA, LLCMounjaro$689$11,51111 claims
GSKTrelegy Ellipta$749$11,42612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Griffin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →